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Abstract
Background: Actinidia arguta, known as sarunashi in Japan, is a vine tree native to east-Asia, including Japan, that
produces small fruit rich in anthocyanins, catechins, vitamin C, chlorophyll, beta-carotene and other polyphenols.
Results: Our study revealed the inhibitory effect of the juice of A. arguta (arguta-juice) toward the mutagenicity of
food-derived carcinogens and polycyclic aromatic hydrocarbons using the Ames test, and antioxidant activity of
arguta-juice as determined using a free radical scavenging assay. The formation of DNA adducts in liver of mice fed
2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) decreased significantly following administration of arguta-
juice. The preventive effect of arguta-juice on the induction of inflammation of mouse ear by 12-O-
tetradecanoylphorbol-13-acetate (TPA) was revealed. The anti-carcinogenic effect of a topically applied partially
purified fraction of A. arguta was revealed on skin tumorigenesis in mice induced by treatment with 7,12-
dimethylbenz(a)anthracene and TPA. In an effort to reveal the mechanisms for antimutagenicity of arguta-juice,
effects on the enzymes that metabolize xenobiotics were examined. Combined effects comprising i) inhibition of
the metabolic activation of mutagens with phase I enzymes, but ii) no prevention on the activity of phase II
detoxification enzyme, UGT, were observed. We also investigated the characterization and partial purification of the
antimutagenic components in A. arguta, which suggested that the components in A. arguta responsible for the
antimutagenicity were water-soluble, heat-labile phenolic compounds.
Conclusions: These results suggested that components in A. arguta are attractive candidates for potential use as
chemopreventive agents.
Keywords: Actinidia arguta, Chemoprevention, Antimutagenesis, DNA adduct, Radical scavenging, Skin cancer,
Enzyme inhibition
Background
Tumor progression is driven by a sequence of randomly
occurring mutations that affect the genes controlling cell
proliferation [1]. A significant portion of human cancers
can be attributed to the consumption of foodstuffs and
smoke-contaminated mutagenic carcinogens. Exposure to
environmental mutagens including food-borne heterocyclic
amines, polyaromatic hydrocarbons and fungal toxins act
through their ability to mutate DNA and/or promote
tumorigenesis [2]. Endogenous oxidative stress, including
the production of reactive oxygen radicals in mitochondria
through aerobic metabolic processes, can also result in oxi-
dative damage and mutations in DNA, which has been im-
plicated in chronic diseases [3]. Inflammation also
contributes to carcinogenesis [4]. Under inflammatory con-
ditions, reactive oxygen species are generated from inflam-
matory cells that can result in oxidative DNA damage. The
DNA damage can cause mutations and has been implicated
in the initiation and/or promotion of inflammation-
mediated carcinogenesis.
Dietary factors play a major role in a variety of human
disorders and are capable of affording protection against
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diseases including cancer [2]. Diets rich in fruit and veg-
etables are known to decrease the risk of many cancers.
Fruit and vegetables rich in polyphenolics have been
studied due to their effect on reducing oxidative stress
and several chronic diseases [5, 6]. In our recent study,
the juice of Vitis coignetiae, which is rich in polyphenols,
significantly inhibited the mutagenicity and clastogeni-
city of several mutagens using the Ames test and micro-
nucleus test [7]. Topical application of the juice of V.
coignetiae significantly decreased the incidence and
multiplicity of tumors in mice skin using a two-stage
tumorigenesis protocol [8]. Actinidia arguta, known as
sarunashi in Japan and hardy kiwi in English name, is a
vine tree native to east-Asia, including Japan [9], that
produces small fruit consumed in the form of fresh fruit
and jam. The fruit is rich in anthocyanins [10], catechins
[11], vitamin C [12], chlorophyll, beta-carotene [13] and
other polyphenols [14, 15]. Antioxidant activity of A.
arguta has been reported in recent studies [16–18], and
components in A. arguta have been reported to possess
anti-allergic activity [19–21].
In the present study, we investigated the effect of the
juice of the fruit of A. arguta on the antimutagenic
activity of food-derived heterocyclic amines and other
carcinogens using the Ames test, antioxidant activity
using a free radical scavenging assay, and DNA adduct
formation induced by 2-amino-3,8-dimethyl-3H-imi-
dazo[4,5-f]quinoxaline (MeIQx). The effect of the juice
of A. arguta on the induction of inflammation of mouse
ear by 12-O-tetradecanoylphorbol-13-acetate (TPA)
was examined, and characterization and partial purifi-
cation of antimutagenic components present in A.
arguta juice were investigated. Furthermore, we evalu-
ated the antitumorigenic activity of a partially purified
fraction of the juice of A. arguta using a two-stage
mouse skin tumorigenesis protocol.
Methods
Materials and animals
Fruits of Actinidia arguta (Hardy kiwifruits) and Actini-
dia deliciosa cv. Hayward (kiwifruits) were used in this
experiment (not use any other parts, leaves, flowers,
roots etc.). Fruit of A. arguta was harvested in the village
Shinjo (Okayama, Japan) and stored at −20 °C until use.
Prior to the experiments, the fruit was defrosted and
then squeezed with a press-squeeze to obtain the juice
(hereafter referred to as arguta-juice). Squeezed juice
was stored at −20 °C until use. Crops comprised a blend
of A. arguta 'Mitsu-ko' and A. arguta 'Hou-ko', unless
otherwise indicated. For the comparison between culti-
vars, fruit was separately harvested from vines of A.
arguta 'Mitsu-ko', A. arguta 'Hou-ko', and a wild vine of
A. arguta found on a hillside in the village Shinjo, the
latter hereafter referred to as A. arguta 'Wild-S'. Half of
the crops from A. arguta 'Mitsu-ko', 'Hou-ko' and '
Wild-S ' were separately squeezed and stored at −20 °C
within 24 h after harvesting (hereafter referred to as
fresh samples). The other half of the crops were stored
at room temperature for three days, squeezed, and then
stored at −20 °C (hereafter referred to as 3rd-day sam-
ples). For the Ames test, arguta-juice was centrifuged at
2200 g for 15 min, and the supernatant was sterilized by
filtration. The filtrate was used for the Ames test with-
out further processing or purification. For the in vivo ex-
periments involving DNA adduct formation, arguta-juice
was freeze-dried and then dissolved in distilled water to
one-third or equal volume of the original juice volume,
hereafter referred to as "arguta-juice (x3)" and "arguta-
juice (x1)", respectively. For the experiments involving
topical application to mice, arguta-juice was freeze-dried
and then dissolved in 66 % acetone to one-third or equal
volume of the original juice volume, hereafter referred to
as "arguta-solution (x3)" and "arguta-solution (x1)",
respectively. The total amount of phenolics in arguta
juice was measured using the method described by
Singleton and Rossi [22]. The quantitative calibration
was performed with standard solutions of gallic acid. Ki-
wifruit (Actinidia deliciosa cv. Hayward) harvested in
Okayama was purchased in local stores in Okayama in
2008, and juice (hereafter referred to as "deliciosa-juice")
was obtained as described above.
Aflatoxin B1 (CAS 1162-65-8), 2-amino-3,8-dimethyl-
3H-imidazo[4,5-f]quinoxaline (MeIQx, CAS 77500-04-
0), 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
(PhIP, CAS 105650-23-5) and 3-amino-1-methyl-5H-pyr-
ido[4,3-b]indole (Trp-P-2, CAS 72254-58-1), benzo(a)-
pyrene (CAS 50-32-8), 7,12-dimethylbenz(a)anthracene
(DMBA, CAS57-97-6), and 12-O-tetradecanoylphorbol-
13-acetate (TPA, CAS16561-29-8) were purchased from
Wako Pure Chemical Co. Ltd. (Osaka, Japan). Polyvinyl-
polypyrrolidone (PVPP) was purchased from Nacalai
Tesque, Inc. Other chemicals used were commercial
products of reagent grade. Salmonella enterica subspe-
cies I, serovar Typhimurium (Salmonella typhimurium)
strain TA98 [hisD3052 ΔuvrB gal bio chl1005 rfa1001/
pKM101], and strain TA100 [hisG46 ΔuvrB gal bio
chl1005 rfa1001/pKM101] were gifts from Dr. B.N.
Ames of the University of California, Berkeley CA [23].
The supernatant fraction of rat liver homogenate (S9)
was prepared from male Sprague–Dawley rats that had
been induced by the administration of polychlorinated
biphenyl (PCB54, with a chlorine content of 54 %, Tokyo
Kasei, Tokyo). The protein content of the S9 fraction
was 43.0 mg/mL. Sprague–Dawley rats and ICR mice
were obtained from Japan SLC, Inc (Hamamatsu, Japan),
C57BL/6 N mice were obtained from Charles River
Japan (Atsugi, Japan), and female SENCAR mice were
born in our laboratory. All experiments were performed
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in accordance with the Safety Guidelines of Okayama
University and the Japanese Government Management
Law for toxic chemicals (No. 303).
Antimutagenicity test
The inhibitory effect of arguta-juice on mutagenicity in-
duced by MeIQx (60 pmol), Trp-P-2 (100 pmol), PhIP
(1.0 nmol), aflatoxin B1 (3.0 nmol), benzo(a)pyrene
(10 nmol) and DMBA (50 nmol) were investigated using
the Ames test [23]. An original sample of arguta-juice,
not dissolved after freeze-drying, was used for the assay.
MeIQx, PhIP, Trp-P-2 and aflatoxin B1 were assayed
using S. typhimurium TA98, and benzo(a)pyrene and
DMBA were assayed using S. typhimurium TA100 in the
presence of S9. The effect of the juice on mutagenicity
was examined as previously described [7]. Experiments
were performed in triplicate. Mutagenic activity (%) as
shown in the figures was derived as follows:
100 revertants in the presence of juiceð Þ – spontaneous revertantsð Þ½ 
 revertants in the absence of juiceð Þ – spontaneous revertantsð Þ½ :
Detection of DNA adducts in mice
C57BL/6 N mice (males, 6 weeks old) were randomly di-
vided into four groups each comprising 8 mice. For in-
vestigation of the influence of arguta-juice on MeIQx-
DNA adduct formation, 1.5 mL of arguta-juice (x1 or
x3) and/or MeIQx (final concentration 0.005 %/diet/day)
was mixed with the control diet (MF powder, Oriental
Yeast Co., Ltd., Tokyo, Japan; 1.5 g) to yield a diet-paste
(3 g). For two days, C57BL/6 N mice received diet-paste
mixed with either water (Group 1), arguta-juice (x1)
(Group 2), or arguta-juice (x3) (Groups 3 & 4) without
MeIQx. Then, for three days, mice were given a diet
(3 g/mouse) mixed with MeIQx (Group 1), arguta-juice
(x1) and MeIQx (Group 2), arguta-juice (x3) and MeIQx
(Group 3), or arguta-juice (x3) (Group 4). On day 6,
mice were sacrificed by cervical dislocation and ex-
tracted tissues were washed with ice-cold KCl (0.15 M)
and then frozen in liquid nitrogen. Samples were stored
at −80 °C until use. The amount of heterocyclic amine-
DNA adduct in the DNA of treated mice tissues shown
in Table 1 was determined by modified adduct-
intensification analysis using the 32P-postlabeling
method [24].
Effect on enzyme activity
Arguta-juice was dissolved in water after freeze-drying
and used for the assay. Sample volumes refer to mL
equivalents of the original juice. The activity of cyto-
chrome P450 1A1 (CYP 1A1) and cytochrome P450 1A2
(CYP1A2) was measured as ethoxyresorufin-O-deethy-
lase (EROD) and methoxyresorufin-O-demethylase
(MROD) activity, respectively, according to the methods
reported by Iwata et al. [25]. Fluorescence intensity was
measured at λ ex 535 nm and λ em 582 nm. Enzyme
activity was expressed as relative fluorescent intensity,
which was calculated for each reaction by normalizing
the control to 100 %. The fluorescence of metabolites
was not altered by the presence of pigments in the juice
samples at the examined concentrations.
The activity of uridine 5'-diphosphoglucuronosyltransfer-
ase (UDP-glucuronosyltransferase, UGT) was determined
by measuring the reduction in absorbance of 4-nitrophenol
at 405 nm as described by Jakoby [26]. Enzyme activity was
expressed as relative fluorescent intensity, which was calcu-
lated for each reaction by normalizing the control to 100 %.
Glutathione S-transferase (GST) activity was determined by
the method of Habig et al. [27], using 1-chloro-2,4-dinitro-
benzene as a substrate. The influence of arguta-juice on
GST activity was investigated by examining the formation
of Glutathione conjugate, and measured by monitoring the
optical density at 340 nm. Enzyme activity as shown was
expressed as a relative intensity, which was calculated for
each reaction by normalizing the control to 100 %. Experi-
ments were performed in triplicate.
Effect on TPA-induced acute edema on the surface of
mouse ears with topical application of arguta-solution
Six-week-old male mice (ICR) weighing 16–18 g were
divided into five groups for the experiment. Mice in
Group 1 (TPA-treated control) and Group 4 (acetone-
treated control) received 20 μL of 66 % acetone applied
on the surface of both ears. Mice in Group 2 received
20 μL of arguta-solution (x1) dissolved in 66 % acetone,
and mice in Groups 3 and 5 received 20 μL of arguta-
solution (x3) dissolved in 66 % acetone, applied on the
inner and outer surface of both ears, respectively. After
Table 1 In vivo effect of arguta-juice in the diet on DNA adduct formation in liver of mice fed with 0.005 % MeIQx
Group No. of mice MeIQx Arguta-juice added to diet Liver weight (g) Adducts/ 108 nucleotide
1 8 0.005 % Water 0.81 ± 0.039 44.9 ± 39.5
2 8 0.005 % arguta-juice (x1) 0.86 ± 0.075 35.9 ± 39.0
3 8 0.005 % arguta-juice (x3) 0.87 ± 0.064 16.5 ± 19.5*
4 2 0 arguta-juice (x3) 0.94 0
Significantly different from Group 1 at *p < 0.05
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30 min, 1.7 nmol of TPA dissolved in acetone was ap-
plied on the surface of both ears of mice in Groups 1–3
for the induction of topical acute edema. Mice in
Groups 4 and 5 received 100 % acetone without TPA.
Thirty minutes following TPA treatment mice were
sacrificed and both ears were removed. Circular sections
(6 mm in diameter) of all treated ears were punched out
using a cork borer and weighed. Edema was quantified
as the weight difference between treatments. Anti-
inflammatory activity was evaluated as the percentage of
edema reduction/induction in the treated mouse relative
to the control mouse. Inhibition (%) as shown in Table 2
was derived as follows:
100 ½ðaverage weight of ear punch treated with
TPA and arguta‐solutionÞ
‐ðaverage weight of ear punch treated
without TPA or arguta‐solutionÞ
½ðaverage weight of ear punch treated with
TPA without arguta‐solutionÞ
‐ ðaverage weight of ear punch treated
without TPA or arguta‐solutionÞÞ:
Fractionation of antimutagenic and radical scavenging
components in arguta-juice
Fractionation of antimutagenic and radical scavenging
components in arguta-juice is outlined in Fig. 1. Briefly,
arguta-juice was subjected to a sequence of solvent-
solvent partitioning, i.e., hexane: ethyl acetate (EtOAc)
(1:1) extraction and EtOAc extraction (hereafter referred
to as Hexane: EtOAc-fr and EtOAc-fr, respectively). The
aqueous fraction after EtOAc extraction was freeze-dried
and the residue was extracted with methanol (MeOH)
and then methanol: water (1:1) (hereafter referred to as
100%MeOH-fr and 50%MeOH-fr, respectively). Hexa-
ne:EtOAc-fr, EtOAc-fr and 100%MeOH-fr were each evap-
orated under reduced pressure to dryness. 50%MeOH-fr
was evaporated to remove methanol and then freeze-dried.
The obtained residues were weighed. For the in vitro
assay using the Ames test and 2,2-diphenyl-1-picryl-
hydrazyl (DPPH) assay, residues were dissolved in
sterilized water. For the in vivo experiments involving
topical application to mice, freeze-dried 50%MeOH-fr
was dissolved in 50 % acetone to one-fifth or one-
tenth volume of the original juice volume, hereafter
referred to as "50%MeOH-fr -solution (x5)" and
"50%MeOH-fr -solution (x10)", respectively. The anti-
mutagenicity of each fraction was monitored for its
effect on MeIQx (60 pmol/plate) mutagenicity assayed
in the presence of S9 with S. typhimurium TA98. The
free radical scavenging activity of arguta-juice and
each fraction was measured using the DPPH scaven-
ging assay [28]. The inhibitory percentage of DPPH
was calculated according to the following equation:
Scavenging effect (%) = (optical density (OD) of con-
trol – OD of sample/OD of control) × 100. The con-
centration of vitamin C was measured by the
indophenol method [29]. The experiments were
performed in triplicate.
Effect on tumor promotion following topical application
of 50%MeOH-fr
Six-week-old female SENCAR mice were randomly di-
vided into four groups each comprising 12 or 13 mice.
The dorsal side of the skin of mice was shaved using an
electric hair cutter at least two days prior to treatment.
Skin tumors were induced chemically using a standard
2-stage initiation-promotion protocol [30]. The initiation
was accomplished using a single topical application of
DMBA (2.5 mg/animal, dissolved in 0.1 mL acetone) on
the dorsal shaved skin of mice in Groups 1–4. Seven
days later, mice in Group 1 (DMBA treated control)
were treated topically with 0.1 mL of 66 % acetone,
while mice in other groups were treated with either
50%MeOH-fr-solution (x5) (Group 2) and/or
50%MeOH-fr-solution (x10) (Groups 3 and 4) dissolved
in 0.1 mL of 50 % acetone per application. Thirty mi-
nutes following treatment, mice in Groups 1–3 were
treated topically with TPA (1.7 nmol) dissolved in
0.1 mL acetone, while mice in Group 4 were treated top-
ically with 0.1 mL acetone as a substitute for the TPA
solution. The TPA and/or 2-dose 50%MeOH-fr treat-
ments were repeated twice per week until the termin-
ation of the experiment 20 weeks from the start of the
DMBA application. During the period, the tumor yield
Table 2 Inhibitory effect of arguta-solution on TPA-induced inflammation of mouse ears by surface treatment. Mouse ear weight is
expressed as mean ± standard deviation
Group Topical treatment 1 Topical treatment 2 No. of ear Average weight of ear punch (mg) Inhibition %
1 66 % Acetone TPA 12 18.00 ± 1.08 0
2 Arguta-solution (x1) TPA 12 14.55 ± 0.86* 29.5
3 Arguta-solution (x3) TPA 12 12.37 ± 1.16* 48.2
4 66 % Acetone Acetone 4 6.31 ± 0.26
5 Arguta-solution (x3) Acetone 4 6.70 ± 0.44
*P < 0.01, significantly different from the TPA-treated group (Group 1) by the t-test
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and incidence were recorded weekly, and tumors >1 mm
in diameter were included in the cumulative total if they
persisted for at least 2 weeks. The data are expressed as
the percentage of mice with tumors and number of tu-
mors per mouse, and are plotted as a function of weeks
during the test.
Effect of heat and PVPP treatment on the
antimutagenicity of arguta-juice and 50%MeOH-fr
For the experiments of heat treatment, sample was
placed in a water bath at 90 °C for 10 min and then
cooled on ice. Heated juice was then centrifuged at
2200 g for 15 min and the supernatant was sterilized by
filtration. For the experiments involving PVPP treat-
ment, 1-mL sample was mixed with 2 mg of PVPP and
then shaken for 30 min. The mixture was then centri-
fuged and the supernatant was sterilized by filtration.
The total amount of phenolics was determined before
and after the PVPP treatment. The antimutagenicity of
the treated and untreated samples was monitored for
the effect on MeIQx (60 pmol/plate) mutagenicity.
Statistical analyses
Data are expressed as means ± standard deviation for
each data point as indicated in each Figure or Table.
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Fig. 2 Effect of arguta-juice (a) and deliciosa-juice (b) on the mutagenicity of MeIQx (60 pmole). An original sample of arguta-juice, not dissolved
after freeze-drying, was used for the assay. MeIQx was assayed using S. typhimurium TA98 in the presence of S9. The number of His+ revertants
per plate found in the absence of juice was 1010 ± 63 for 60 pmol of MeIQx. Harvesting of the fruit of A. arguta were performed in 2008 (circles)
and 2010 (triangles). Harvesting of the fruit of A. deliciosa was performed in 2008
Arguta-juice (500 mL, dry weight 57.7 g)
Extracted with hexane:EtOAc (1:1)
Hexane:EtOAc-fr (0.12 g) aqueous fr. 
Extracted with EtOAc 











Fig. 1 Flow chart detailing the isolation of an active component from arguta-juice. Arguta-juice was subjected to a sequence of solvent-solvent
partitioning. The aqueous fraction after EtOAc extraction was freeze-dried and the residue was extracted with methanol. Weight in parentheses of
the dry weight of each fraction from 500 mL of original juice
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and Kaplan-Meier method with KaleidaGraph (Synergy
Software, Reading, PA), Excel add-in soft (SSRI CO. Ltd,
Tokyo, Japan), and JMP (JMP Japan, Tokyo, Japan).
Results
Antimutagenicity of arguta-juice
Arguta-juice and deliciosa-juice significantly inhibited
MeIQx mutagenicity (Fig. 2). The number of His+ rever-
tants per plate found in the absence of juice was 1010 ±
63 for 60 pmol of MeIQx and the number of His+ rever-
tants spontaneously formed was 42 ± 0.7 with S. typhi-
murium TA98 in the presence of metabolic activation.
The amount of arguta-juice needed for 50 % inhibition
(ID50) of the mutagenicity of MeIQx was approximately
10 μl/plate (Fig. 2a), while that of deliciosa-juice was ap-
proximately 90 μL/plate (Fig. 2b). Since a smaller
amount of arguta-juice was needed to inhibit the muta-
genicity of MeIQx compared to deliciosa-juice, arguta-
juice was selected for further investigations of antimuta-
genicity. The reproducibility of the antimutagenicity to-
ward MeIQx was confirmed using the fruit of A. arguta
harvested in 2008 and 2010 (Fig. 2a). Arguta-juice inhib-
ited the mutagenicity of Trp-P-2, PhIP, aflatoxin B1,
benzo(a)pyrene and DMBA (Fig. 3). The number of His+
revertants per plate found in the absence of juice was
4592 ± 505 for 100 pmol of Trp-P-2, 877 ± 31 and for
1.0 nmol of PhIP, 1036 ± 95 for 3.0 nmol of aflatoxin B1
with S. typhimurium TA98 in the presence of metabolic
activation, 1166 ± 189 for 50 nmol of DMBA, and 1056
± 102 for 10 nmol of benzo(a)pyrene with S. typhimur-
ium TA100 in the presence of metabolic activation. The
number of His+ revertants spontaneously formed was
118 ± 23.5 with S. typhimurium TA100 in the presence
of metabolic activation. The amount of arguta-juice re-
quired to achieve an ID50 value with Trp-P-2, PhIP, afla-
toxin B1, benzo(a)pyrene and DMBA was approximately
8.0, 8.0, 15, 35 and 20 μL/plate, respectively, similar with
that obtained with MeIQx.
The difference between cultivars of A. arguta (Wild-S,
Mitsu-ko and Hou-ko) and the effect of preservation on
antimutagenicity were examined (Fig. 4). The ID50 value
was 3 μL/plate for the arguta-juice of Wild-S (first and
third-day samples), 18 μL/plate for Mitsu-ko (third-day
sample), 4 μl/plate for Hou-ko (fresh sample), and
greater than 25 μL/plate for Mitsu-ko (fresh sample) and
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Fig. 3 Effect of arguta-juice on the mutagenicity of Trp-P-2 (a), PhIP (b), aflatoxin B1 (c), benzo(a)pyrene (d), and DMBA (e). Harvesting of the fruit
of A. arguta was performed in 2008. MeIQx, PhIP, Trp-P-2 and aflatoxin B1 were assayed using S. typhimurium TA98, and benzo(a)pyrene and
DMBA were assayed using S. typhimurium TA100 in the presence of S9
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of Wild-S needed for ID50 was lower than that of Mitsu-ko
and Hou-ko both for the fresh and third-day samples. The
total phenolic content was 11.1 mg/mL and 17.3 mg/mL
for Hou-ko (fresh and third-day sample), 17.0 mg/mL and
15.5 mg/mL for Mitsu-ko (fresh and third-day sample), and
12.5 mg/mL and 18.7 mg/mL for Wild-S (first and third-
day samples), respectively. The effect of preservation
at room temperature on antimutagenicity varied in
these cases.
Effect of arguta-juice on the formation of DNA adducts
in vivo
The in vivo effect of arguta-juice on the formation of
DNA adducts in mice fed MeIQx was investigated. The
diet-paste given to mice was completely eaten before
9 a.m. the following day. MeIQx-induced DNA adducts
were formed in liver of mice fed MeIQx in their diet
(Table 1 Groups 1–3). No adducts were observed in the
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Fig. 4 Comparison of the antimutagenicity of arguta juice between cultivars A. arguta ' Wild-S ' (a), A. arguta 'Mitsu-ko' (b), and A. arguta 'Hou-ko'
(c) on the mutagenicity of MeIQx (60 pmole). Comparison between fresh samples (triangles) and third-day samples (circles) are also shown. Harvesting
of the fruit of A. arguta was performed in 2011
Fig. 5 Effect of arguta-juice on CYP1A1-mediated EROD activity (a), CYP-1A2-mediated MROD activity (b), UGT activity (c), and GST activity (d).
Relative activity is shown, where 100 % is defined as the activity of each enzyme in the absence of juice
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for five days (Table 1 Group 4). The formation of DNA
adducts formed in liver of mice given MeIQx in the diet
decreased significantly following administration of
arguta-juice (x3) compared with mice given MeIQx
without juice (Table 1). No significant differences in
body and liver weight or notable clinical signs of illness
were observed amongst Groups 1–4 throughout the
study (data not shown).
Effect of arguta-juice on the catalytic activity of CYPs,
UGT and GST
In an effort to reveal the mechanisms for antimutageni-
city of arguta-juice, we examined the effects on the en-
zymes that metabolize xenobiotics, we quantified the
amount of specific metabolite produced by individual
CYPs using typical substrates in the absence or presence
of the juice. Arguta-juice significantly inhibited the activ-
ity of EROD (CYP1A1) and MROD (CYP1A2) (Fig. 5a
and b). Relative enzymatic activity is shown in Fig. 5a, b,
where 100 % is defined as the activity of CYP1A1 and
CYP1A2 in the absence of juice. The ID50 value of
arguta-juice observed when using CYP1A1 and CYP1A2
was 8.0 and 5.0 μL/mL of reaction mixture, respectively.
When arguta-juice was added to the reaction mixture
of phase II enzymes, the activity of UGT increased in a
dose-dependent manner to 115 % of the control (Fig. 5c),
whereas the activity of GST was inhibited (Fig. 5d) and
the ID50 value of arguta-juice with GST was 18 μL/mL
of reaction mixture.
Effect of topical application of arguta-solution on TPA-
induced acute edema on the surface of mouse ears
The anti-inflammatory activity of arguta-solution was
evaluated in a mouse ear model. A single topical applica-
tion of TPA induced ear edema in mice. Topical applica-
tion of arguta-solution inhibited TPA-induced edema of
mouse ear in a dose-dependent manner (Table 2). When
20 μL of arguta-solution (x3) was applied to mouse ears
prior to TPA treatment, 48.2 % inhibition of inflamma-
tion was achieved.
Partial purification and fractionation of antimutagenic
and radical scavenging components in arguta-juice
Partial purification and fractionation of antimutagenic and
radical scavenging components in arguta-juice was per-
formed as outlined in Fig. 1. Based on spectrophotometric
determinations, the total phenolic content in arguta-juice
was 9.31 mg/ml, determined as gallic acid equivalents
(Table 3). Phenolics were distributed throughout every
fraction. The concentration of vitamin C in arguta-juice
was 1.48 mg/mL, whereas that in 50 %-MeOH-fr was less
than the detection limit (0.075 mg/mL).
The antimutagenic and radical scavenging activity of
each fraction were examined (Fig. 6). The antimutagenic
components were located in 50%MeOH-fr and
100%MeOH-fr, and the ID50 values when examining
antimutagenicity were 60 and 270 μL eq. of arguta-juice,
respectively (Table 3 and Fig. 6a). The ID50 value of the
starting material (arguta-juice) when examining the mu-
tagenicity of MeIQx was 10 μL, and the antimutagenicity
of 50%MeOH-fr and 100%MeOH-fr was 1/6 and 1/27
that of arguta-juice, respectively. The dry weight of
100%MeOH-fr and 50%MeOH-fr was 88.7 and 5.9 % of
the arguta-juice, respectively. Therefore, the specific ac-
tivity determined for 50%MeOH-fr and 100%MeOH-fr
with respect to antimutagenicity was 2.88 and 0.042, re-
spectively, calculated by normalizing the activity of
arguta-juice to 1 (Table 3).
The amount of DPPH radical decreased significantly
in the presence of arguta-juice, as shown in Fig. 6b. The
amount of arguta-juice needed to achieve a 50 % de-
crease in DPPH, i.e. the 50 % scavenging dose (ED50)
was approximately 10 μl/plate (Table 3, Fig. 6b). The
radical scavenging activity was also located predomin-
antly in 50%MeOH-fr and 100%MeOH-fr (Fig. 6b). Since
the ED50 of 50%MeOH-fr and 100%MeOH-fr was 50
and 15 μL eq. of arguta-juice, the radical scavenging ac-
tivity of 50%MeOH-fr and 100%MeOH-fr was 1/5 and
1/1.5 that of arguta-juice, respectively (Table 3). The
specific activity of 50%MeOH-fr and 100%MeOH-fr in
terms of radical scavenging activity was calculated as
Table 3 Partial purification of 1 l or arguta-juice; Dry weight, phenolics and biological activity in each fraction
Fraction Dry weight Phenolics Antimutagenicity ID50 (Specific activity
b) DPPH scavenging activity ED50 (Specific activity)
mg/mL eq.a (yield) mg/mL eq. (yield) μL eq. (foldb) μL eq. (fold)
Arguta-juice 115.3 (1) 9.31 (1) 10 (1) 10 (1)
Hexane 0.24 (0.0021) 0.181 (0.019) (−) (−)
-EtOAc-fr
EtOAc-fr 3.70 (0.032) 1.20 (0.13) (−) (−)
100%MeOH-fr 102.3 (0.887) 2.24 (0.24) 270 (0.042) 15 (0.75)
50%MeOH-fr. 6.82 (0.059) 1.16 (0.13) 60 (2.88) 50 (3.39)
Residue-fr. 2.26 (0.020) 1.06 (0.11) (−) (−)
amL eq. mL equivalent of starting material, i.e., arguta-juice
bSpecific activity = (ID50 of the original arguta-juice / ID50 of each fraction)/ (yield of dry weight)
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3.39 and 0.75, respectively, calculated by normalizing the
activity of arguta-juice to 1 (Table 3). Hence, the specific
activity in terms of both antimutagenicity and radical
scavenging activity was highest in 50%MeOH-fr
(Table 3).
Antitumorigenesis study
Significant differences were observed concerning tumor
incidence between Groups 1 and 2, and Groups 1 and 3
(P < 0.01) (Fig. 7a). Skin tumors appeared in the 5th
week with TPA application in Group 1, whereas similar
tumors appeared in the 8th and 9th weeks in groups
treated with 50%MeOH-fr (Groups 2 and 3), respect-
ively. The final mean number of tumors per mouse was
14.2, 4.8 and 3.5 for Groups 1, 2 and 3, respectively
(Fig. 7b). A significant difference was observed concern-
ing tumor multiplicity between Groups 1 and 2, and
Groups 1 and 3 (P < 0.01). None of the mice in Group 4
developed skin tumors. No significant differences were
observed with respect to animal growth and noticeable
clinical signs of illness in Groups 1–4 throughout the
two-stage mouse skin tumor study (data not shown).
Effect of heat and PVPP treatment
Stability to heat was examined in an effort to investigate
the nature of antimutagenic substances in arguta-juice. The
antimutagenicity of arguta-juice and 50%MeOH-fr
decreased following heat treatment at 90 °C for 10 min
(Fig. 8a, b). Greater amounts of heated-treated arguta-juice
and 50%MeOH-fr were needed to inhibit the mutagenicity
of MeIQx compared to that of the original sample, which
indicated that the antimutagenic substances in arguta-juice
and 50%MeOH-fr comprised heat-labile compounds.
PVPP has been reported to absorb and remove phenolic
compounds from solvent [31]. In an effort to determine
whether the antimutagenic substances in arguta-juice
comprised phenolics, arguta-juice and 50%MeOH-fr were
treated with PVPP. Based on the spectrophotometric
determination, the amounts of total phenolic content in
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Fig. 6 Inhibitory effect toward the mutagenicity of MeIQx (a) and radical scavenging activity (b) of each fraction. Original arguta-juice (half-closed


















































Fig. 7 Effect of topical application of 50%MeOH-fr of arguta-juice on skin tumorigenesis in mice. a Tumor incidence and (b) tumor multiplicity were
measured in female SENCAR mice treated with DMBA and TPA (Group 1, circles); DMBA, TPA and 50%MeOH-fr (x 5) (Group 2, squares); DMBA, TPA and
50%MeOH-fr (x 10) (Group 3, triangles); or DMBA and 50%MeOH-fr (x 10) without TPA (Group 4, diamonds). Each data point represents the average
number per group of mice. *P < 0.01, significantly different from Group 1
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decreased to 51.2 and 38.4 %, respectively. Following
PVPP treatment, ID50 values with respect to the antimuta-
genicity of arguta-juice and 50%MeOH-fr increased, and
greater amounts of arguta-juice and 50%MeOH-fr were
needed to inhibit the mutagenicity of MeIQx (Fig. 8c, d).
Discussion
We investigated the antimutagenic effect of arguta-juice on
well known carcinogens using the Ames test and results
showed that arguta-juice inhibited the mutagenicity of het-
erocyclic amines (MeIQx, Trp-P-2 and PhIP), aflatoxin B1,
and polycyclic aromatic hydrocarbons (benzo(a)pyrene and
DMBA) (Figs. 2 and 3). Although the total phenolic con-
tent and antioxidant activity of the fruit of A. arguta was
reported to be comparable to that of A. deliciosa [16], the
antimutagenicity of the juice of the fruit was in the order
A. arguta >A. deliciosa (Fig. 2). There was no correlation
between the antimutagenicity and the amount of total phe-
nolics of the cultivars (Fig. 4). The antimutagenic activity
of the fruit of A. arguta differed between cultivars, and
may reflect differing contents of antimutagenic compo-
nents. The antimutagenicity of arguta-juice was in the
order Wild-S >Hou-Ko >Mitsu-ko. Storage of the fruit at
room temperature resulted in no consensus changes to the
antimutagenicity. Three days after the harvest, the antimu-
tagenicity of the arguta-juice of Wild-S showed no
significant changes, whereas the antimutagenicity of the
arguta-juice of Mitsu-ko increased and that of the arguta-
juice of Hou-ko decreased during storage. There may be
various metabolic changes that occur during storage that
leads to a change in the content of antimutagenic
substances.
The in vivo effect of arguta-juice was then investi-
gated. Results showed that arguta-juice had a protective
effect against DNA adduct formation in liver induced by
MeIQx [32]. Addition of arguta-juice to the diet de-
creased the number of DNA adducts formed in liver
(Table 1). Heterocyclic amines including MeIQx usually
exist in cooked food, and their importance as a dietary
component has been generally accepted with respect to
cancer development.
Antimutagenic mechanisms were also investigated.
Metabolic pathways including bioactivation and bio-
inactivation are possible targets for antimutagenicity, and
the inhibition of phase I enzyme activity by exogenous
compounds has been observed [33]. Mutagens examined
and shown in Figs. 2, 3 and 4 require bio-conversion to
express mutagenicity. The principal pathways of bio-
inactivation involve CYP-mediated N-oxidation of the
exocyclic amine, CYP-mediated ring-oxidation, followed
by N-glucuronidation with UGT [34]. Bio-activation of
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Fig. 8 Effect of heat and PVPP treatment on the antimutagenic activity of arguta juice toward the mutagenicity of MeIQx. Effect of arguta-juice
(circle) and heat-treated juice (triangle) (a); effect of 50%MeOH-fr (circles) and heat-treated 50%MeOH-fr (triangles) (b); effect of arguta-juice (circles)
and PVPP-treated juice (triangles) (c); and effect of 50%MeOH-fr (circles) and PVPP-treated 50%MeOH-fr (triangles) (d)
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with phase I enzymes (CYPs) followed by O-sulfonation
or O-acetylation with phase II enzymes of sulfotransferase
and acetyltransferase, those of aflatoxin B1 and polycyclic
aromatic hydrocarbons involves ring-epoxylation with
phase I enzymes. Arguta-juice decreased the activity of
phase I enzymes (EROD and MROD) and GST, but not
UGT. Combined effects comprising i) inhibition of the
metabolic activation of mutagens with phase I enzymes,
but ii) not prevented activity of phase II detoxication
enzyme, UGT, for the elimination of mutagens via glucur-
onidation, may be responsible for the observed antimuta-
genicity of arguta-juice.
We also investigated the in vivo effect of the anti-
inflammatory activity of arguta-solution. Tumor promo-
tion is an essential stage of carcinogenesis and inflam-
mation is a key factor in cancer promotion. Topical
application of arguta-solution to mouse ear resulted in
marked suppression of acute edema induced by TPA
(Table 2). TPA causes instant irritation of mouse ear,
and leads to fluid accumulation and edema, characteris-
tic of the acute inflammatory response. Our results sug-
gested that certain components in arguta-juice can be
transcutaneously passed through to target cells and
eventually lead to suppression of the inflammatory
response in mouse ear.
We performed a partial purification of arguta-juice in
an effort to characterize the active components. Antimu-
tagenic and radical scavenging substances were located
in the aqueous fraction and were not extracted with
hexane-EtOAc or EtOAc, indicating that these sub-
stances are water-soluble (Table 3, Fig. 6). Although
88.7 % of the components in arguta-juice, calculated on
the basis of dry-weight, was distributed in 100%MeOH-
fr, the ID50 value of 50%MeOH-fr with respect to the
mutagenicity of MeIQx was lower than that of
100%MeOH-fr, indicating that most of the antimuta-
genic substances were present in 50%MeOH-fr. The spe-
cific activity of the radical scavenging effect was also
highest in 50%MeOH-fr.
We then investigated the antitumorigenic effect of
topical applications of 50%MeOH-fr in the multistage
carcinogenesis model in mouse skin. Topical application
of 50%MeOH-fr prior to TPA treatment afforded signifi-
cant protection against tumor promotion in the mouse
skin tumorigenesis model (Fig. 7). Our findings showed
that component(s) in 50%MeOH-fr revealed antimuta-
genic, radical scavenging and antitumorigenic activities.
Although one radical scavenging and water-soluble
compound known in the fruit of A. arguta is vitamin C
[12], the concentration of vitamin C in 50%MeOH-fr was
less than the detection limit. Therefore, vitamin C alone
may not be responsible for the observed radical scaven-
ging and antimutagenic activity in 50%MeOH-fr. Other
potential candidates present as part of the active
components of arguta-juice are polyphenols. Fruit is an
important source of polyphenols in the human diet [35].
The content of polyphenols in A. arguta, being 9.31 mg/
mL, is higher than that in kiwifruit and apple (1.12 mg/g
and 0.20 mg/mL of juice, respectively [15]). In arguta-
juice, 12.5 % of the phenolics were present in 50%MeOH-
fr (Table 3). PVPP-treatment indicated that the antimuta-
genic substances in arguta-juice and 50%MeOH-fr com-
prised phenolics (Fig. 8b, d). These results suggested that
the antimutagenic components in arguta-juice and
50%MeOH-fr were water-soluble, heat-labile phenolic
compounds. Further purification and identification of
active ingredients will be performed in future.
Conclusions
The present studies have demonstrated that arguta-juice
inhibited the mutagenic activity of carcinogens including
MeIQx, a food-borne carcinogen, and DMBA, a model
compound of tumor initiation. Arguta-juice also inhib-
ited DNA adduct formation in liver of mouse fed
MeIQx, and inhibited the induction of acute inflamma-
tion of mouse ear induced by TPA, a typical promoter.
Moreover, components in 50%MeOH-fr of arguta-juice
led to a reduction in existing mouse skin tumors in-
duced by DMBA-TPA. These results suggested that
components in A. arguta are attractive candidates for
potential use as chemopreventive agents.
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